|
|
Office Locations:
|
51 Astor Place, 10th Floor
New York, NY 10003
Phone: 646-205 5300
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
The Perceptive Xontogeny Venture Funds are Perceptive Advisors' investment vehicles focused purely on early-stage, private venture investments in life sciences companies. Primary investments for the Fund include companies that are seeking a lead investor for Series A financings, which include both companies that are seeded and incubated at Xontogeny (see profile), as well as companies that are seeded and incubated by other organizations, accelerators and seed investors. The PXV Funds are also open to participating in syndicated Series A financings as a co-lead or passive investor with other venture capital firms. The firm announced (May 2021) the closing of Perceptive Xontogeny Venture Fund II, LP (PXV Fund II) with $515 million in capital commitments in an oversubscribed fund to further the firm's early-stage life sciences platform. The close of PXV Fund II more than triples assets under management to $725 million in less than two years since the closing of the inaugural PXV Fund I, which launched Perceptive's early-stage venture fund strategy.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
